A 54- year- old African- American woman was diagnosed with stage IIIC high- grade serous ovarian 24 months ago. After an exploratory laparotomy resulted in successful resection of all gross disease, she received six cycles of intravenous paclitaxel/ carboplatin with a resultant clinical complete remission. She now presents with a rising CA- 125 (three successive monthly elevated values with the last value at 360 U/ ml). She is asymptomatic. A CT scan of the abdomen/ pelvis shows no evidence of recurrent disease. Which of the following would you recommend at this point?
Download an excerpt from the Bethesda Handbook of Clinical Oncology, a comprehensive review of the management of ovarian cancer, emphasizing practical information that can be applied in everyday in fast-moving patient care situations.
Article: Tumor Gene Test Shows Promise of Better Predicting Ovarian Cancer Survival
Survival rates among women with ovarian cancer vary greatly, making the ability to determine who potentially faces a more aggressive form of the disease challenging for oncologists. Determined to find a better way to predict ovarian cancer survival rates than stage and age, a team of researchers recently developed a tumor gene test and found that the results offered improved prediction rates.
Understanding Ovarian Cancer chart is a user friendly chart that explains ovarian cancer in easy to understand language. View risk factors and signs and symptoms, describes diagnosis, and discusses treatment options and prevention strategies.
A 40- year-old woman presents to her gynecologist because her sister, aged 42, was recently diagnosed with serous ovarian carcinoma and she was found to carry a deleterious germline BRCA1 mutation. The patient reports a strong family history of both breast and ovarian cancer, also including her mother (breast cancer). Testing reveals that she also carries the deleterious BRCA1 mutation. She has completed child-bearing. Which of the following would you recommend?